Blood transfusion: friend or foe

The Incidence Rate of Acute Transfusion Reactions in Thalassemia Patients Referred to the Shiraz Thalassemia Centre, Shiraz, Iran, Before and After the Establishment of the Hemovigilance System

This study aimed to investigate the incidence rate of acute transfusion reactions in thalassemia patients before and after the establishment of the hemovigilance system. This prospective descriptive study was conducted at the Dastgheyb Hospital, Shiraz, Iran, from 2009 to 2012. The incidence rate, type, imputability and severity of acute transfusion reactions were compared in thalassemia patients before and after the establishment of the hemovigilance system. A total of 741 thalassemia patients were referred to the Dastgheyb Hospital for transfusions during the study period. The incidence rates of acute transfusion reactions were reported as 0.06% (11 out of 16,214), 0.11% (23 out of 19,660), 0.10% (28 out of 26,129) and 0.2% (50 out of 24,121), respectively, from 2009 to 2012. The most frequent were major allergic reactions and febrile non hemolytic transfusion reactions (FNHTR). The transfusion reactions were increasingly reported after the establishment of the hemovigilance system in 2011 (p < 0.05). The establishment of the hemovigilance system can improve reporting of transfusion reactions. Moreover, evaluation of the incidence rate of transfusion reactions is necessary to design preventive measures to reduce transfusion risks.

Blood transfusion among thalassemia patients: A single Egyptian center experience

Background:

Although red cell transfusions are lifesavers for patients with thalassemia, they are responsible for a series of complications and expose the patients to a variety of risks.

Material and Methods:

This cross-sectional study included 464 Egyptian beta(β) thalassemia major patients whose age ranged between 10 months and 31 years (mean 10.2 ± 6.6 years). All patients were subjected to thorough history taking with special emphasis on blood transfusions regarding rate of blood transfusion, type of received blood, and history of previous transfusion reactions in addition to type of chelation and compliance to iron chelation therapy and history of diabetes. Serum ferritin and pretransfusion hemoglobin assessment were done for all patients.

Results:

The mean pretransfusion hemoglobin level was 5.7 ± 1.16 g/dl. Allergic reactions were observed in 3.9% of the patients during the period of the study, while the history of previous allergic reaction was given by 72% of the patients. Deferiprone showed better compliance (58.6%) than deferoxamine (26.3%). The prevalence of diabetes was 10.1% among the studied group. On comparing diabetics to nondiabetics, serum ferritin, transfusion intervals, and age were statistically higher among diabetics (P<0.001).

Conclusion:

Lower pretransfusion hemoglobin and high rate of prevalence of diabetes, in addition to better compliance to deferiprone than deferoxamine, were detected among the patients.

Anemia and transfusion therapy: an update

Anemia is one of the most prevalent diseases in the general population and is a very frequently found condition in medical and surgical patients in all medical specialties. A good evaluation of its clinical impact and its therapeutic possibilities is essential. Allogenic blood transfusion is a useful procedure in anemia management, although it has important adverse effects. It is the responsibility of the clinician to know and to take into account all the available alternatives for the treatment of anemia. Blood transfusions, erythropoiesis-stimulating agents, iron therapy (oral and endovenous) and other therapeutic alternatives must be rationally used, in accordance with the currently available clinical evidence. This review article summarizes some epidemiological characteristics of anemia, its clinical evaluation and the main therapeutic possibilities based on the present knowledge, placing special emphasis on the critically ill patient.

[Anemia and transfusion therapy: an update]

Anemia is one of the most prevalent diseases in the general population and is a very frequently found condition in medical and surgical patients in all medical specialties. A good evaluation of its clinical impact and its therapeutic possibilities is essential. Allogenic blood transfusion is a useful procedure in anemia management, although it has important adverse effects. It is the responsibility of the clinician to know and to take into account all the available alternatives for the treatment of anemia. Blood transfusions, erythropoiesis-stimulating agents, iron therapy (oral and endovenous) and other therapeutic alternatives must be rationally used, in accordance with the currently available clinical evidence. This review article summarizes some epidemiological characteristics of anemia, its clinical evaluation and the main therapeutic possibilities based on the present knowledge, placing special emphasis on the critically ill patient.